Next-generation CD40 agonists for cancer immunotherapy

References

• Vonderheide RH. CD40 agonist antibodies in cancer immunotherapy. Annu Rev Med. 2020 Jan 27;71(1):47–58. doi: 10.1146/annurev-med-062518-045435
   PubMedGoogle Scholar
• Ellmark P, Mangsbo SM, Furebring C, et al. Kick-starting the cancer-immunity cycle by targeting CD40. Oncoimmunology. 2015 Jul;4(7):e1011484. doi: 10.1080/2162402X.2015.1011484
   PubMed Web of Science ®Google Scholar
• Beatty GL, Li Y, Long KB. Cancer immunotherapy: activating innate and adaptive immunity through CD40 agonists. Expert Rev Anticancer Ther. 2017 Feb;17(2):175–186. doi: 10.1080/14737140.2017.1270208
   PubMed Web of Science ®Google Scholar
• Beatty GL, Chiorean EG, Fishman MP, et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science. 2011 Mar 25;331(6024):1612–1616. doi: 10.1126/science.1198443
   PubMed Web of Science ®Google Scholar
• Enell Smith K, Deronic A, Hägerbrand K, et al. Rationale and clinical development of CD40 agonistic antibodies for cancer immunotherapy. Expert Opin Biol Ther. 2017 Jun;21(12):1–12. doi: 10.1080/14712598.2021.1934446
   Google Scholar
• Prenen H, Borbath I, Geboes KP, et al. Efficacy and safety of mitazalimab in combination with mFOLFIRINOX in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): an interim analysis of the optimize-1 phase 1b/2 study. J Clin Oncol. 2023;41(16_suppl):4139–4139. doi: 10.1200/JCO.2023.41.16_suppl.4139
   Web of Science ®Google Scholar
• Banchereau J, Bazan F, Blanchard D, et al. The CD40 antigen and its ligand. Annu Rev Immunol. 1994;12(1):881–922. doi: 10.1146/annurev.iy.12.040194.004313
   PubMedGoogle Scholar
• Elgueta R, Benson MJ, de Vries VC, et al. Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol Rev. 2009 May;229(1):152–172. doi: 10.1111/j.1600-065X.2009.00782.x
   PubMed Web of Science ®Google Scholar
• Peters AL, Stunz LL, Bishop GA. CD40 and autoimmunity: the dark side of a great activator. Semin Immunol. 2009 Oct;21(5):293–300. doi: 10.1016/j.smim.2009.05.012
   PubMed Web of Science ®Google Scholar
• Korniluk A, Kemona H, Dymicka-Piekarska V. Multifunctional CD40L: pro- and anti-neoplastic activity. Tumour Biol. 2014 Oct;35(10):9447–9457. doi: 10.1007/s13277-014-2407-x
   PubMed Web of Science ®Google Scholar
• Eliopoulos AG, Young LS. The role of the CD40 pathway in the pathogenesis and treatment of cancer. Curr Opin Pharmacol. 2004 Aug;4(4):360–367. doi: 10.1016/j.coph.2004.02.008
   PubMed Web of Science ®Google Scholar
• Werneburg BG, Zoog SJ, Dang TT, et al. Molecular characterization of CD40 signaling intermediates. J Biol Chem. 2001 Nov 16;276(46):43334–43342. doi: 10.1074/jbc.M104994200
   PubMed Web of Science ®Google Scholar
• Kornbluth RS, Stempniak M, Stone GW. Design of CD40 agonists and their use in growing B cells for cancer immunotherapy. Int Rev Immunol. 2012 Aug;31(4):279–288. doi: 10.3109/08830185.2012.703272
   PubMed Web of Science ®Google Scholar
• Soto M, Filbert EL, Yang H, et al. Use of high-dimensional and spatial immune profiling to explore sotigalimab (CD40 agonist) activation of antigen presenting cells and T cells in the tumor microenvironment in patients with esophageal/gastroesophageal junction cancer. J Clin Oncol. 2023;41(4_suppl):450–450. doi: 10.1200/JCO.2023.41.4_suppl.450
   Google Scholar
• Padron LJ, Maurer DM, O’Hara MH, et al. Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial. Nat Med. 2022 Jun 3;28(6):1167–1177. doi: 10.1038/s41591-022-01829-9
   PubMed Web of Science ®Google Scholar
• Vonderheide RH, Flaherty KT, Khalil M, et al. Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol. 2007 Mar 1;25(7):876–883. doi: 10.1200/JCO.2006.08.3311
   PubMed Web of Science ®Google Scholar
• Kelley SK, Gelzleichter T, Xie D, et al. Preclinical pharmacokinetics, pharmacodynamics, and activity of a humanized anti-CD40 antibody (SGN-40) in rodents and non-human primates. Br J Pharmacol. 2006 Aug;148(8):1116–1123. doi: 10.1038/sj.bjp.0706828
   PubMed Web of Science ®Google Scholar
• Moreno V, Perets R, Peretz-Yablonski T, et al. A phase 1 study of intravenous mitazalimab, a CD40 agonistic monoclonal antibody, in patients with advanced solid tumors. Invest New Drugs. 2022 Dec 20;41(1):93–104. doi: 10.1007/s10637-022-01319-2
   PubMed Web of Science ®Google Scholar
• Mangsbo SM, Broos S, Fletcher E, et al. The human agonistic CD40 antibody ADC-1013 eradicates bladder tumors and generates T-cell-dependent tumor immunity. Clin Cancer Res. 2015 Mar 1;21(5):1115–1126. doi: 10.1158/1078-0432.CCR-14-0913
   PubMed Web of Science ®Google Scholar
• Vonderheide RH, Glennie MJ. Agonistic CD40 antibodies and cancer therapy. Clin Cancer Res. 2013 Mar 1;19(5):1035–1043. doi: 10.1158/1078-0432.CCR-12-2064
   PubMed Web of Science ®Google Scholar
• Andersson H, Sobti A, Jimenez DG, et al. Early pharmacodynamic changes measured using RNA sequencing of peripheral blood from patients in a phase i study with mitazalimab, a potent CD40 agonistic monoclonal antibody. Cells. 2023;12(19):2365. doi: 10.3390/cells12192365
   PubMed Web of Science ®Google Scholar
• Deronic A, Nilsson A, Thagesson M, et al. The human anti-CD40 agonist antibody mitazalimab (ADC-1013; JNJ-64457107) activates antigen-presenting cells, improves expansion of antigen-specific T cells, and enhances anti-tumor efficacy of a model cancer vaccine in vivo. Cancer Immunol Immun. 2021 May 5;70(12):3629–3642. doi: 10.1007/s00262-021-02932-5
   PubMed Web of Science ®Google Scholar
• Irenaeus SMM, Nielsen D, Ellmark P, et al. First-in-human study with intratumoral administration of a CD40 agonistic antibody, ADC-1013, in advanced solid malignancies. Int J Cancer. 2019 Sep 1;145(5):1189–1199. doi: 10.1002/ijc.32141
   PubMed Web of Science ®Google Scholar
• Filbert EL, Bjorck PK, Srivastava MK, et al. APX005M, a CD40 agonist antibody with unique epitope specificity and Fc receptor binding profile for optimal therapeutic application. Cancer Immunol Immun. 2021 Jan 3;70(7):1853–1865. doi: 10.1007/s00262-020-02814-2
   PubMed Web of Science ®Google Scholar
• O’Hara MH, O’Reilly EM, Varadhachary G, et al. CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study. Lan Oncol. 2021;22(1):118–131. doi: 10.1016/S1470-2045(20)30532-5
   PubMed Web of Science ®Google Scholar
• Weiss SA, Djureinovic D, Jessel S, et al. A phase I study of APX005M and cabiralizumab with or without nivolumab in patients with melanoma, kidney cancer, or non-small cell lung cancer resistant to anti-PD-1/PD-L1. Clin Cancer Res. 2021 Sep 1;27(17):4757–4767. doi: 10.1158/1078-0432.CCR-21-0903
   PubMed Web of Science ®Google Scholar
• Weiss SA, Sznol M, Shaheen M, et al. A phase II trial of the CD40 agonistic antibody sotigalimab (APX005M) in combination with nivolumab in subjects with metastatic melanoma with confirmed disease progression on anti-PD-1 therapy. Clin Cancer Res. 2024 Jan 5;30(1):74–81. doi: 10.1158/1078-0432.CCR-23-0475
   PubMedGoogle Scholar
• Reni M. APX005M, a CD40 monoclonal antibody, for patients with pancreatic adenocarcinoma. Lancet Oncol. 2021 Jan;22(1):10–11. doi: 10.1016/S1470-2045(20)30724-5
   PubMed Web of Science ®Google Scholar
• Powderly JD, Tolcher A, LoRusso P, et al. A phase I study of CD40 agonist ABBV-927 plus OX40 agonist ABBV-368 with or without the PD-1 inhibitor budigalimab in patients with advanced solid tumors. J Clin Oncol. 2020;38(15_suppl):TPS3147–TPS3147. doi: 10.1200/JCO.2020.38.15_suppl.TPS3147
   Google Scholar
• Coveler AL, Smith DC, Phillips T, et al. Phase 1 dose-escalation study of SEA-CD40: a non-fucosylated CD40 agonist, in advanced solid tumors and lymphomas. J Immunother Cancer. 2023 Jun;11(6):e005584. doi: 10.1136/jitc-2022-005584
   PubMed Web of Science ®Google Scholar
• Sanborn R, Hauke R, Gabrail N, et al. 405 CDX1140–01, a phase 1 dose-escalation/expansion study of CDX-1140 alone (Part 1) and in combination with CDX-301 (Part 2) or pembrolizumab (Part 3). J Immunother Cancer. 2020;8(Suppl 3):A246–A246.
   Google Scholar
• Vitale LA, Thomas LJ, He LZ, et al. Development of CDX-1140, an agonist CD40 antibody for cancer immunotherapy. Cancer Immunol Immunother. 2018 Oct 31;68(2):233–245. doi: 10.1007/s00262-018-2267-0
   PubMed Web of Science ®Google Scholar
• Ruter J, Antonia SJ, Burris HA, et al. Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumors. Cancer Biol Ther. 2010 Nov 15;10(10):983–993. doi: 10.4161/cbt.10.10.13251
   PubMed Web of Science ®Google Scholar
• Beatty GL, Torigian DA, Chiorean EG, et al. A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma. Clin Cancer Res. 2013 Nov 15;19(22):6286–6295. doi: 10.1158/1078-0432.CCR-13-1320
   PubMed Web of Science ®Google Scholar
• Nowak AK, Cook AM, McDonnell AM, et al. A phase 1b clinical trial of the CD40-activating antibody CP-870,893 in combination with cisplatin and pemetrexed in malignant pleural mesothelioma. Ann Oncol. 2015 Dec;26(12):2483–2490. doi: 10.1093/annonc/mdv387
   PubMed Web of Science ®Google Scholar
• Byrne KT, Betts CB, Mick R, et al. Neoadjuvant selicrelumab, an agonist CD40 antibody, induces changes in the tumor microenvironment in patients with resectable pancreatic cancer. Clin Cancer Res. 2021 Jun 10;27(16):4574–4586. doi: 10.1158/1078-0432.CCR-21-1047
   PubMed Web of Science ®Google Scholar
• Barlesi F, Lolkema M, Rohrberg KS, et al. 291 Phase Ib study of selicrelumab (CD40 agonist) in combination with atezolizumab (anti-PD-L1) in patients with advanced solid tumors. J Immunother Cancer. 2020;8(Suppl 3):A178–A178.
   Google Scholar
• Nyesiga B, Levin M, Sall A, et al. RUBY(R) - a tetravalent (2+2) bispecific antibody format with excellent functionality and IgG-like stability, pharmacology and developability properties. MAbs. 2024 Jan;16(1):2330113. doi: 10.1080/19420862.2024.2330113
   PubMed Web of Science ®Google Scholar
• Hagerbrand K, Varas L, Deronic A, et al. Bispecific antibodies targeting CD40 and tumor-associated antigens promote cross-priming of T cells resulting in an antitumor response superior to monospecific antibodies. J Immunother Cancer. 2022 Nov;10(11). doi: 10.1136/jitc-2022-005018
   PubMed Web of Science ®Google Scholar
• Surowka M, Schaefer W, Klein C. Ten years in the making: application of CrossMab technology for the development of therapeutic bispecific antibodies and antibody fusion proteins. MAbs. 2021 Jan;13(1):1967714. doi: 10.1080/19420862.2021.1967714
   PubMed Web of Science ®Google Scholar
• Sum E, Rapp M, Durr H, et al. The tumor-targeted CD40 agonist CEA-CD40 promotes T cell priming via a dual mode of action by increasing antigen delivery to dendritic cells and enhancing their activation. J Immunother Cancer. 2022 Mar;10(3):e003264. doi: 10.1136/jitc-2021-003264
   PubMed Web of Science ®Google Scholar
• Sumitomo Y, Kawasaki K, Tezuka Y, et al. Abstract 5311: KK2269, an epithelial cell adhesion molecule-targeted CD40 agonist, stimulates anti-tumor immunity resulting in sustained anti-tumor effect against mouse intrahepatic tumor without hepatotoxicity. Cancer Res. 2024;84(6_Supplement):5311–5311. doi: 10.1158/1538-7445.AM2024-5311
   Google Scholar
• Tezuka Y, Kawasaki K, Sumitomo Y, et al. Abstract 5310: KK2269, an epithelial cell adhesion molecule-targeted CD40 agonist, demonstrates antitumor effects in combination with standard therapies for NSCLC. Cancer Res. 2024;84(6_Supplement):5310–5310. doi: 10.1158/1538-7445.AM2024-5310
   Google Scholar
• Liu F, Gong W, Yang Y, et al. 1143 5T4-CD40 bispecific antibodies activate immune responses in a 5T4-dependent manner. J Immunother Cancer. 2022;10(Suppl 2):A1187–A1187.
   Google Scholar
• Sun W, Wang X, Wang D, et al. CD40×HER2 bispecific antibody overcomes the CCL2-induced trastuzumab resistance in HER2-positive gastric cancer. J Immunother Cancer. 2022 Jul;10(7):e005063. doi: 10.1136/jitc-2022-005063
   PubMed Web of Science ®Google Scholar
• Lu L, Liu N, Fan K, et al. A tetravalent single chain diabody (CD40/HER2) efficiently inhibits tumor proliferation through recruitment of T cells and anti-HER2 functions. Mol Immunol. 2019 May;109:149–156. doi: 10.1016/j.molimm.2019.03.001
   PubMed Web of Science ®Google Scholar
• de Silva S, Fromm G, Shuptrine CW, et al. CD40 enhances type I interferon responses downstream of CD47 blockade, bridging innate and adaptive immunity. Cancer Immunol Res. 2020 Feb;8(2):230–245. doi: 10.1158/2326-6066.CIR-19-0493
   PubMed Web of Science ®Google Scholar
• Luo H, Meng Z, Rong J, et al. Abstract 5559: Development of a novel PD-L1xCD40 bispecific antibody with excellent efficacy and safety profile for cancer therapy. Cancer Res. 2022;82(12_Supplement):5559–5559. doi: 10.1158/1538-7445.AM2022-5559
   Google Scholar
• Rigamonti N, Veitonmaki N, Domke C, et al. A multispecific anti-CD40 DARPin construct induces tumor-selective CD40 activation and tumor regression. Cancer Immunol Res. 2022 May 3;10(5):626–640. doi: 10.1158/2326-6066.CIR-21-0553
   PubMed Web of Science ®Google Scholar
• Chen S, Lin Y, Zhou X, et al. Abstract 2366: Balancing efficacy and toxicity of a fibroblast activation protein dependent tetravalent CD40 agonist antibody for cancer therapy. Cancer Res. 2024;84(6_Supplement):2366–2366. doi: 10.1158/1538-7445.AM2024-2366
   Google Scholar
• Sum E, Rapp M, Frobel P, et al. Fibroblast activation protein α-targeted CD40 agonism abrogates systemic toxicity and enables administration of high doses to induce effective antitumor immunity. Clin Cancer Res. 2021 Mar 26;27(14):4036–4053. doi: 10.1158/1078-0432.CCR-20-4001
   PubMed Web of Science ®Google Scholar
• Labiano S, Roh V, Godfroid C, et al. CD40 agonist targeted to fibroblast activation protein alpha synergizes with radiotherapy in murine HPV-Positive head and neck tumors. Clin Cancer Res. 2021 Jul 15;27(14):4054–4065. doi: 10.1158/1078-0432.CCR-20-4717
   PubMed Web of Science ®Google Scholar
• Mega A, Mebrahtu A, Aniander G, et al. A PDGFRB- and CD40-targeting bispecific AffiMab induces stroma-targeted immune cell activation. MAbs. 2023 Jan;15(1):2223750. doi: 10.1080/19420862.2023.2223750
   PubMed Web of Science ®Google Scholar
• Coloma MJ, Morrison SL. Design and production of novel tetravalent bispecific antibodies. Nature Biotechnol. 1997;15(2):159–163. doi: 10.1038/nbt0297-159
   PubMed Web of Science ®Google Scholar
• Liu B, Hui L, Liu C, et al. Abstract 1852: A novel PD1-CD40 bispecific antibody YH008 induces potent anti-tumor activity in vivo by PD1 dependent activation of CD40 signaling. Cancer Res. 2021;81(13_Supplement):1852–1852. doi: 10.1158/1538-7445.AM2021-1852
   Web of Science ®Google Scholar
• Zhang Z, Jia Y, Huang W, et al. 1403 1403 A bispecific antibody targeting PD1 and CD40 displays potent anti-tumor efficacy through two mechanisms: PD1 blockade and PD1-dependent CD40 agonism. J Immunother Cancer. 2023;11(Suppl 1):A1561–A1561.
   Google Scholar
• Muik A, Adams Iii HC, Gieseke F, et al. DuoBody-CD40x4-1BB induces dendritic-cell maturation and enhances T-cell activation through conditional CD40 and 4-1BB agonist activity. J Immunother Cancer. 2022 Jun;10(6):e004322. doi: 10.1136/jitc-2021-004322
   PubMed Web of Science ®Google Scholar
• Ye S, Cohen D, Belmar NA, et al. A bispecific molecule targeting Cd40 and tumor antigen mesothelin enhances tumor-specific immunity. Cancer Immunol Res. 2019;7(11):1864–1875. doi: 10.1158/2326-6066.CIR-18-0805
   PubMed Web of Science ®Google Scholar
• Luke JJ, Fong L, Chung K, et al. Phase 1 study evaluating safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of ABBV‑428, A mesothelin‑cd40 bispecific, in patients with advanced solid tumors. Ann Oncol. 2019;30(suppl_5):v475–v532. doi: 10.1093/annonc/mdz253.046
   Google Scholar
• Hollevoet K, Mason-Osann E, Liu XF, et al. In vitro and in vivo activity of the low-immunogenic antimesothelin immunotoxin RG7787 in pancreatic cancer. Mol Cancer Ther. 2014 Aug;13(8):2040–2049. doi: 10.1158/1535-7163.MCT-14-0089-T
   PubMed Web of Science ®Google Scholar
• Del Bano J, Florès-Florès R, Josselin E, et al. A bispecific antibody-based approach for targeting mesothelin in triple negative breast cancer [original research]. Front Immunol. 2019 Jul 10;10(1593). doi: 10.3389/fimmu.2019.01593
   PubMedGoogle Scholar
• Karizak AZ, Salmasi Z, Gheibihayat SM, et al. Understanding the regulation of “Don’t Eat-Me” signals by inflammatory signaling pathways in the tumor microenvironment for more effective therapy. J Cancer Res Clin Oncol. 2023 Jan;149(1):511–529. doi: 10.1007/s00432-022-04452-w
   PubMed Web of Science ®Google Scholar
• Lakhani NJ, Stewart DB, Richardson DL, et al. Phase 1 dose escalation study of SL-172154 (SIRPα-Fc-CD40L) in platinum-resistant ovarian cancer. J Clin Oncol. 2023;41(16_suppl):5544–5544. doi: 10.1200/JCO.2023.41.16_suppl.5544
   Web of Science ®Google Scholar
• Sun C, Mezzadra R, Schumacher TN. Regulation and function of the PD-L1 checkpoint. Immunity. 2018 Mar 20;48(3):434–452. doi: 10.1016/j.immuni.2018.03.014
   PubMed Web of Science ®Google Scholar
• Muik A, Kosoff R, Gieseke F, et al. DuoBody-CD40×4-1BB (GEN1042) induces dendritic-cell maturation and enhances T-cell activation and effector functions in vitro by conditional CD40 and 4-1BB agonist activity. [Abstract]. AACR. 2021.
   Google Scholar
• Johnson M, Lopez J, LoRusso P, et al. 493 First-in-human phase 1/2 trial to evaluate the safety and initial clinical activity of DuoBody®-CD40×4–1BB (GEN1042) in patients with advanced solid tumors. J Immunother Cancer. 2021;9(Suppl 2):A525–A525. doi: 10.1136/jitc-2021-SITC2021.493
   Google Scholar
• Dual-targeting approach for CD40 and 4-1BB. Cancer Discov. 2022;12(1):9–10. doi: 10.1158/2159-8290.CD-NB2021-0403
   PubMed Web of Science ®Google Scholar
• Lehmann CH, Heger L, Heidkamp GF, et al. Direct delivery of antigens to dendritic cells via antibodies specific for endocytic receptors as a promising strategy for future therapies. Vaccines (Basel). 2016 Mar 28;4(2):8. doi: 10.3390/vaccines4020008
   PubMed Web of Science ®Google Scholar
• Chen P, Liu X, Sun Y, et al. Dendritic cell targeted vaccines: Recent progresses and challenges. Hum Vaccin Immunother. 2016 Mar 3;12(3):612–622. doi: 10.1080/21645515.2015.1105415
   PubMed Web of Science ®Google Scholar
• Dhodapkar MV, Sznol M, Zhao B, et al. Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205. Sci Transl Med. 2014 Apr 16;6(232):232ra51. doi: 10.1126/scitranslmed.3008068
   PubMed Web of Science ®Google Scholar
• Gargett T, Abbas MN, Rolan P, et al. Phase I trial of Lipovaxin-MM, a novel dendritic cell-targeted liposomal vaccine for malignant melanoma. Cancer Immunol Immun. 2018 Sep;67(9):1461–1472. doi: 10.1007/s00262-018-2207-z
   PubMed Web of Science ®Google Scholar
• Morse MA, Chapman R, Powderly J, et al. Phase I study utilizing a novel antigen-presenting cell-targeted vaccine with Toll-like receptor stimulation to induce immunity to self-antigens in cancer patients. Clin Cancer Res. 2011 Jul 15;17(14):4844–4853. doi: 10.1158/1078-0432.CCR-11-0891
   PubMed Web of Science ®Google Scholar
• Yin W, Gorvel L, Zurawski S, et al. Functional specialty of CD40 and dendritic cell surface lectins for exogenous antigen presentation to CD8(+) and CD4(+) T Cells. EBioMedicine. 2016 Mar;5:46–58. doi: 10.1016/j.ebiom.2016.01.029
   PubMed Web of Science ®Google Scholar
• Chatterjee B, Smed-Sorensen A, Cohn L, et al. Internalization and endosomal degradation of receptor-bound antigens regulate the efficiency of cross presentation by human dendritic cells. Blood. 2012 Sep 6;120(10):2011–2020. doi: 10.1182/blood-2012-01-402370
   PubMed Web of Science ®Google Scholar
• Schmitt S, Tahk S, Lohner A, et al. Fusion of bacterial flagellin to a dendritic cell-targeting alphaCD40 antibody construct coupled with viral or leukemia-specific antigens enhances dendritic cell maturation and activates peptide-responsive T Cells. Front Immunol. 2020;11:602802. doi: 10.3389/fimmu.2020.602802
   PubMed Web of Science ®Google Scholar
• Ceglia V, Zurawski S, Montes M, et al. Anti-CD40 antibodies fused to CD40 ligand have superagonist properties. J Immunol. 2021 Oct 15;207(8):2060–2076. doi: 10.4049/jimmunol.2000704
   PubMed Web of Science ®Google Scholar
• Graham JP, Authie P, Yu CI, et al. Targeting dendritic cells in humanized mice receiving adoptive T cells via monoclonal antibodies fused to Flu epitopes. Vaccine. 2016 Sep 22;34(41):4857–4865. doi: 10.1016/j.vaccine.2016.08.071
   PubMed Web of Science ®Google Scholar
• Cheng L, Wang Q, Li G, et al. TLR3 agonist and CD40-targeting vaccination induces immune responses and reduces HIV-1 reservoirs. J Clin Invest. 2018 Oct 1;128(10):4387–4396. doi: 10.1172/JCI99005
   PubMed Web of Science ®Google Scholar
• Zurawski G, Shen X, Zurawski S, et al. Superiority in rhesus macaques of targeting HIV-1 Env gp140 to CD40 versus LOX-1 in combination with replication-competent NYVAC-KC for induction of Env-specific antibody and T Cell responses. J Virol. 2017 May 1;91(9). doi: 10.1128/JVI.01596-16
   PubMed Web of Science ®Google Scholar
• Flamar AL, Xue Y, Zurawski SM, et al. Targeting concatenated HIV antigens to human CD40 expands a broad repertoire of multifunctional CD4+ and CD8+ T cells. AIDS. 2013 Aug 24;27(13):2041–2051. doi: 10.1097/QAD.0b013e3283624305
   PubMed Web of Science ®Google Scholar
• Chen J, Zurawski G, Zurawski S, et al. A novel vaccine for mantle cell lymphoma based on targeting cyclin D1 to dendritic cells via CD40. J Hematol Oncol. 2015 Apr 14;8(1):35. doi: 10.1186/s13045-015-0131-7
   PubMedGoogle Scholar
• BarrTA MA, Carlring J, Heath AW. A potent adjuvant effect of CD40 antibody attached to antigen. Immunology. 2003;109(1):87–92. doi: 10.1046/j.1365-2567.2003.01634.x
   PubMed Web of Science ®Google Scholar
• Ishihara J, Ishihara A, Potin L, et al. Improving efficacy and safety of agonistic anti-CD40 antibody through extracellular matrix affinity. Mol Cancer Ther. 2018 Nov;17(11):2399–2411. doi: 10.1158/1535-7163.MCT-18-0091
   PubMed Web of Science ®Google Scholar
• Carlring J, Szabo MJ, Dickinson R, et al. Conjugation of lymphoma idiotype to CD40 antibody enhances lymphoma vaccine immunogenicity and antitumor effects in mice. Blood. 2012 Mar 1;119(9):2056–2065. doi: 10.1182/blood-2011-05-355461
   PubMed Web of Science ®Google Scholar
• Flamar AL, Zurawski S, Scholz F, et al. Noncovalent assembly of anti-dendritic cell antibodies and antigens for evoking immune responses in vitro and in vivo. J Immunol. 2012 Sep 1;189(5):2645–2655. doi: 10.4049/jimmunol.1102390
   PubMed Web of Science ®Google Scholar
• Eltahir M, Laurén I, Lord M, et al. An adaptable antibody‐based platform for flexible synthetic peptide delivery built on agonistic CD40 antibodies. Adv Ther. 2022;5(7). doi: 10.1002/adtp.202200008
   Google Scholar
• Broos S, Sandin LC, Apel J, et al. Synergistic augmentation of CD40-mediated activation of antigen-presenting cells by amphiphilic poly(gamma-glutamic acid) nanoparticles. Biomaterials. 2012 Sep;33(26):6230–6239. doi: 10.1016/j.biomaterials.2012.05.011
   PubMed Web of Science ®Google Scholar
• Kwong B, Liu H, Irvine DJ. Induction of potent anti-tumor responses while eliminating systemic side effects via liposome-anchored combinatorial immunotherapy. Biomaterials. 2011;32(22):5134–5147. doi: 10.1016/j.biomaterials.2011.03.067
   PubMed Web of Science ®Google Scholar
• Yan H, Lin G, Liu Z, et al. Nano-adjuvants and immune agonists promote antitumor immunity of peptide amphiphiles. Acta Biomater. 2023 Apr 15;161:213–225. doi: 10.1016/j.actbio.2023.02.034
   PubMed Web of Science ®Google Scholar
• Rosalia RA, Cruz LJ, van Duikeren S, et al. CD40-targeted dendritic cell delivery of PLGA-nanoparticle vaccines induce potent anti-tumor responses. Biomaterials. 2015 Feb;40:88–97. doi: 10.1016/j.biomaterials.2014.10.053
   PubMed Web of Science ®Google Scholar
• Correa S, Meany EL, Gale EC, et al. Injectable nanoparticle-based hydrogels enable the safe and effective deployment of immunostimulatory CD40 agonist antibodies. Adv Sci. 2022 Oct;9(28):e2103677. doi: 10.1002/advs.202103677
   Web of Science ®Google Scholar
• Yan J, Zhang Y, Du S, et al. Nanomaterials-mediated co-stimulation of toll-like receptors and CD40 for antitumor immunity. Adv Mater. 2022 Nov;34(47):e2207486. doi: 10.1002/adma.202207486
   PubMed Web of Science ®Google Scholar
• Liljenfeldt L, Dieterich LC, Dimberg A, et al. CD40L gene therapy tilts the myeloid cell profile and promotes infiltration of activated T lymphocytes. Cancer Gene Ther. 2014 Mar;21(3):95–102. doi: 10.1038/cgt.2014.2
   PubMed Web of Science ®Google Scholar
• Loskog A, Dzojic H, Vikman S, et al. Adenovirus CD40 ligand gene therapy counteracts immune escape mechanisms in the tumor Microenvironment. J Immunol. 2004 Jun 1;172(11):7200–7205. doi: 10.4049/jimmunol.172.11.7200
   PubMed Web of Science ®Google Scholar
• Dzojic H, Loskog A, Totterman TH, et al. Adenovirus-mediated CD40 ligand therapy induces tumor cell apoptosis and systemic immunity in the TRAMP-C2 mouse prostate cancer model. Prostate. 2006 Jun 1;66(8):831–838. doi: 10.1002/pros.20344
   PubMed Web of Science ®Google Scholar
• Malmstrom PU, Loskog AS, Lindqvist CA, et al. AdCD40L immunogene therapy for bladder carcinoma–the first phase I/IIa trial. Clin Cancer Res. 2010 Jun 15;16(12):3279–3287. doi: 10.1158/1078-0432.CCR-10-0385
   PubMed Web of Science ®Google Scholar
• Loskog A, Maleka A, Mangsbo S, et al. Immunostimulatory AdCD40L gene therapy combined with low-dose cyclophosphamide in metastatic melanoma patients. Br J Cancer. 2016 Apr 12;114(8):872–880. doi: 10.1038/bjc.2016.42
   PubMed Web of Science ®Google Scholar
• Irenaeus S, Hellstrom V, Wenthe J, et al. Intratumoral immunostimulatory AdCD40L gene therapy in patients with advanced solid tumors. Cancer Gene Ther. 2021 Nov;28(10–11):1188–1197. doi: 10.1038/s41417-020-00271-8
   PubMed Web of Science ®Google Scholar
• Wierda WG, Cantwell MJ, Woods SJ, et al. CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia. Blood. 2000;96(9):2917–2924. doi: 10.1182/blood.V96.9.2917
   PubMed Web of Science ®Google Scholar
• Naing A, Rosen L, Camidge RD, et al. 1011P FORTITUDE phase I study of NG-350A, a novel tumour-selective adenoviral vector expressing an anti-CD40 agonist antibody: monotherapy dose escalation results. Annals Oncology. 2021;32:S853–S854. doi: 10.1016/j.annonc.2021.08.1395
   Web of Science ®Google Scholar
• Lillie T, O’Hara M, Ottensmeier C, et al. Abstract CT213: A multicenter phase 1a/b study of NG-350A, a tumor-selective anti-CD40-antibody expressing adenoviral vector, and pembrolizumab in patients with metastatic or advanced epithelial tumors (FORTIFY). Cancer Res. 2022;82(12_Supplement):CT213–CT213. doi: 10.1158/1538-7445.AM2022-CT213
   Web of Science ®Google Scholar
• Eileen MOR, Mark HOH, George F, et al. 765 NG-350A, a tumor-selective anti-CD40 agonist expressing therapeutic, gemcitabine/nab-paclitaxel and ipilimumab for untreated metastatic pancreatic adenocarcinoma: cohort C of the REVOLUTION trial. J Immunother Cancer. 2023;11(Suppl 1):A860.
   Google Scholar
• Kvedaraite E, Ginhoux F. Human dendritic cells in cancer. Sci Immunol. 2022 Apr;7(70):eabm9409. doi: 10.1126/sciimmunol.abm9409
   PubMed Web of Science ®Google Scholar
• Jimenez DG, Altunbulakli C, Swoboda S, et al. Single-cell analysis of myeloid cells in HPV+ tonsillar cancer [Original Research]. Front Immunol. 2023 Jan 19;13:13. doi: 10.3389/fimmu.2022.1087843
   Web of Science ®Google Scholar
• Sun Y, Wu L, Zhong Y, et al. Single-cell landscape of the ecosystem in early-relapse hepatocellular carcinoma. Cell. 2021 Jan 21;184(2):404–421 e16. doi: 10.1016/j.cell.2020.11.041
   PubMed Web of Science ®Google Scholar
• Zhang Q, He Y, Luo N, et al. Landscape and dynamics of single immune cells in hepatocellular carcinoma. Cell. 2019 Oct 31;179(4):829–845 e20. doi: 10.1016/j.cell.2019.10.003
   PubMed Web of Science ®Google Scholar
• Zilionis R, Engblom C, Pfirschke C, et al. Single-cell transcriptomics of human and mouse lung cancers reveals conserved myeloid populations across individuals and species. Immunity. 2019 May 21;50(5):1317–1334 e10. doi: 10.1016/j.immuni.2019.03.009
   PubMed Web of Science ®Google Scholar
• Maier B, Leader AM, Chen ST, et al. A conserved dendritic-cell regulatory program limits antitumour immunity. Nature. 2020 Apr 01;580(7802):257–262. doi: 10.1038/s41586-020-2134-y
   PubMed Web of Science ®Google Scholar
• Santegoets SJ, Duurland CL, Jordanova EJ, et al. CD163+ cytokine-producing cDC2 stimulate intratumoral type 1 T cell responses in HPV16-induced oropharyngeal cancer. J Immunother Cancer. 2020;8(2):e001053. doi: 10.1136/jitc-2020-001053
   PubMed Web of Science ®Google Scholar
• Steele NG, Carpenter ES, Kemp SB, et al. Multimodal mapping of the tumor and peripheral blood immune landscape in human pancreatic cancer. Nat Cancer. 2020 Nov 01;1(11):1097–1112. doi: 10.1038/s43018-020-00121-4
   PubMedGoogle Scholar
• Wattenberg MM, Coho H, Herrera VM, et al. Cancer immunotherapy via synergistic coactivation of myeloid receptors CD40 and Dectin-1. Sci Immunol. 2023;8(89):eadj5097. doi: 10.1126/sciimmunol.adj5097
   PubMed Web of Science ®Google Scholar
• Pombo Antunes AR, Scheyltjens I, Lodi F, et al. Single-cell profiling of myeloid cells in glioblastoma across species and disease stage reveals macrophage competition and specialization. Nat Neurosci. 2021 Apr 01;24(4):595–610. doi: 10.1038/s41593-020-00789-y
   PubMed Web of Science ®Google Scholar
• Wu Y, Yang S, Ma J, et al. Spatiotemporal immune landscape of colorectal cancer liver metastasis at single-cell level. Cancer Discov. 2022;12(1):134–153. doi: 10.1158/2159-8290.CD-21-0316
   PubMed Web of Science ®Google Scholar
• Kürten CHL, Kulkarni A, Cillo AR, et al. Investigating immune and non-immune cell interactions in head and neck tumors by single-cell RNA sequencing. Nat Commun. 2021 Dec 17;12(1):7338. doi: 10.1038/s41467-021-27619-4
   PubMed Web of Science ®Google Scholar
• Zhang L, Li Z, Skrzypczynska KM, et al. Single-cell analyses inform mechanisms of myeloid-targeted therapies in colon cancer. Cell. 2020;181(2):442–459.e29. doi: 10.1016/j.cell.2020.03.048
   PubMed Web of Science ®Google Scholar
• Hildner K, Edelson BT, Purtha WE, et al. Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity. Science. 2008 Nov 14;322(5904):1097–1100. doi: 10.1126/science.1164206
   PubMed Web of Science ®Google Scholar
• Djureinovic D, Wang M, Kluger HM. Agonistic CD40 antibodies in cancer treatment. Cancers (Basel). 2021;13(6):1302. doi: 10.3390/cancers13061302
   PubMed Web of Science ®Google Scholar
• Garris CS, Wong JL, Ravetch JV, et al. Dendritic cell targeting with Fc-enhanced CD40 antibody agonists induces durable antitumor immunity in humanized mouse models of bladder cancer. Sci Transl Med. 2021 May 19;13(594). doi: 10.1126/scitranslmed.abd1346
   PubMed Web of Science ®Google Scholar
• Salomon R, Rotem H, Katzenelenbogen Y, et al. Bispecific antibodies increase the therapeutic window of CD40 agonists through selective dendritic cell targeting. Nat Cancer. 2022 Mar 01;3(3):287–302. doi: 10.1038/s43018-022-00329-6
   PubMedGoogle Scholar
• Wu R, Ohara RA, Jo S, et al. Mechanisms of CD40-dependent cDC1 licensing beyond costimulation. Nat Immunol. 2022 Oct 21;23(11):1536–1550. doi: 10.1038/s41590-022-01324-w
   PubMed Web of Science ®Google Scholar
• Murgaski A, Kiss M, Van Damme H, et al. Efficacy of CD40 agonists is mediated by distinct cDC subsets and subverted by suppressive macrophages. Cancer Res. 2022 Oct 17;82(20):3785–3801. doi: 10.1158/0008-5472.CAN-22-0094
   PubMed Web of Science ®Google Scholar
• Mantovani A, Allavena P, Marchesi F, et al. Macrophages as tools and targets in cancer therapy. Nat Rev Drug Discov. 2022 Nov 01;21(11):799–820. doi: 10.1038/s41573-022-00520-5
   PubMed Web of Science ®Google Scholar
• Bied M, Ho WW, Ginhoux F, et al. Roles of macrophages in tumor development: a spatiotemporal perspective. Cell Mol Immunol. 2023 Sep 01;20(9):983–992. doi: 10.1038/s41423-023-01061-6
   PubMed Web of Science ®Google Scholar
• Lim CY, Chang JH, Lee WS, et al. CD40 agonists alter the pancreatic cancer microenvironment by shifting the macrophage phenotype toward M1 and suppress human pancreatic cancer in organotypic slice cultures. Gut Liver. 2022;16(4):645–659. doi: 10.5009/gnl210311
   PubMed Web of Science ®Google Scholar
• Liu H-C, Davila Gonzalez D, Viswanath DI, et al. Sustained intratumoral administration of agonist CD40 antibody overcomes immunosuppressive tumor microenvironment in pancreatic cancer. Adv Sci. 2023;10(9):2206873. doi: 10.1002/advs.202206873
   Web of Science ®Google Scholar
• Cabrita R, Lauss M, Sanna A, et al. Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature. 2020 Jan 15;577(7791):561–565. doi: 10.1038/s41586-019-1914-8
   PubMed Web of Science ®Google Scholar
• Helmink BA, Reddy SM, Gao J, et al. B cells and tertiary lymphoid structures promote immunotherapy response. Nature. 2020 Jan 15;577(7791):549–555. doi: 10.1038/s41586-019-1922-8
   PubMed Web of Science ®Google Scholar
• Petitprez F, de Reynies A, Keung EZ, et al. B cells are associated with survival and immunotherapy response in sarcoma. Nature. 2020 Jan 15;577(7791):556–560. doi: 10.1038/s41586-019-1906-8
   PubMed Web of Science ®Google Scholar
• Lapointe R, Bellemare-Pelletier A, Housseau F, et al. CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T Cells1. Cancer Res. 2003;63(11):2836–2843.
   PubMed Web of Science ®Google Scholar
• Carpenter EL, Mick R, Ruter J, et al. Activation of human B cells by the agonist CD40 antibody CP-870,893 and augmentation with simultaneous toll-like receptor 9 stimulation. J Transl Med. 2009 Nov 11;7(1):93. doi: 10.1186/1479-5876-7-93
   PubMedGoogle Scholar
• van Hooren L, Vaccaro A, Ramachandran M, et al. Agonistic CD40 therapy induces tertiary lymphoid structures but impairs responses to checkpoint blockade in glioma. Nat Commun. 2021 Jul 05;12(1):4127. doi: 10.1038/s41467-021-24347-7
   PubMed Web of Science ®Google Scholar
• Vono M, Lin A, Norrby-Teglund A, et al. Neutrophils acquire the capacity for antigen presentation to memory CD4+ T cells in vitro and ex vivo. Blood. 2017;129(14):1991–2001. doi: 10.1182/blood-2016-10-744441
   PubMed Web of Science ®Google Scholar
• Khan SY, Kelher MR, Heal JM, et al. Soluble CD40 ligand accumulates in stored blood components, primes neutrophils through CD40, and is a potential cofactor in the development of transfusion-related acute lung injury. Blood. 2006;108(7):2455–2462. doi: 10.1182/blood-2006-04-017251
   PubMed Web of Science ®Google Scholar
• Ren Y, Wang R, Weng S, et al. Multifaceted role of redox pattern in the tumor immune microenvironment regarding autophagy and apoptosis. Mol Cancer. 2023 Aug 10;22(1):130. doi: 10.1186/s12943-023-01831-w
   PubMed Web of Science ®Google Scholar
• Enell Smith K, Deronic A, Hagerbrand K, et al. Rationale and clinical development of CD40 agonistic antibodies for cancer immunotherapy. Expert Opin Biol Ther. 2021 Dec;21(12):1635–1646. doi: 10.1080/14712598.2021.1934446
   PubMed Web of Science ®Google Scholar
• Llopiz D, Dotor J, Zabaleta A, et al. Combined immunization with adjuvant molecules poly(I: C) and anti-CD40 plus a tumor antigen has potent prophylactic and therapeutic antitumor effects. Cancer Immunol Immun. 2008 Jan;57(1):19–29. doi: 10.1007/s00262-007-0346-8
   PubMed Web of Science ®Google Scholar
• Yin W, Duluc D, Joo H, et al. Therapeutic HPV Cancer Vaccine Targeted to CD40 Elicits Effective CD8+ T-cell Immunity. Cancer Immunol Res. 2016 Oct;4(10):823–834. doi: 10.1158/2326-6066.CIR-16-0128
   PubMed Web of Science ®Google Scholar
• Nimanong S, Ostroumov D, Wingerath J, et al. CD40 signaling drives potent cellular immune responses in heterologous cancer vaccinations. Cancer Res. 2017 Apr 15;77(8):1918–1926. doi: 10.1158/0008-5472.CAN-16-2089
   PubMed Web of Science ®Google Scholar
• Lau SP, van Montfoort N, Kinderman P, et al. Dendritic cell vaccination and CD40-agonist combination therapy licenses T cell-dependent antitumor immunity in a pancreatic carcinoma murine model. J Immunother Cancer. 2020 Jul;8(2):e000772. doi: 10.1136/jitc-2020-000772
   PubMed Web of Science ®Google Scholar
• Nowak AK, Robinson BW, Lake RA. Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors. Cancer Res. 2003 Aug 1;63(15):4490–4496.
   PubMed Web of Science ®Google Scholar
• Long KB, Gladney WL, Tooker GM, et al. IFNgamma and CCL2 cooperate to redirect tumor-infiltrating monocytes to degrade fibrosis and enhance chemotherapy efficacy in pancreatic carcinoma. Cancer Discov. 2016 Apr;6(4):400–413. doi: 10.1158/2159-8290.CD-15-1032
   PubMed Web of Science ®Google Scholar
• Yao W, Maitra A, Ying H. Recent insights into the biology of pancreatic cancer. EBioMedicine. 2020 Mar;53:102655. doi: 10.1016/j.ebiom.2020.102655
   PubMed Web of Science ®Google Scholar
• Ma HS, Poudel B, Torres ER, et al. A CD40 Agonist and PD-1 antagonist antibody reprogram the microenvironment of nonimmunogenic tumors to allow T-cell-mediated anticancer activity. Cancer Immunol Res. 2019 Mar;7(3):428–442. doi: 10.1158/2326-6066.CIR-18-0061
   PubMed Web of Science ®Google Scholar
• Ngiow SF, Young A, Blake SJ, et al. Agonistic CD40 mAb-Driven IL12 reverses resistance to anti-PD1 in a T-cell-rich tumor. Cancer Res. 2016 Nov 1;76(21):6266–6277. doi: 10.1158/0008-5472.CAN-16-2141
   PubMed Web of Science ®Google Scholar
• Zippelius A, Schreiner J, Herzig P, et al. Induced PD-L1 expression mediates acquired resistance to agonistic anti-CD40 treatment. Cancer Immunol Res. 2015 Mar;3(3):236–244. doi: 10.1158/2326-6066.CIR-14-0226
   PubMed Web of Science ®Google Scholar
• Selvaraj S, Raundhal M, Patidar A, et al. Anti-VEGF antibody enhances the antitumor effect of CD40. Int J Cancer. 2014 Oct 15;135(8):1983–1988. doi: 10.1002/ijc.28833
   PubMed Web of Science ®Google Scholar
• Kashyap AS, Schmittnaegel M, Rigamonti N, et al. Optimized antiangiogenic reprogramming of the tumor microenvironment potentiates CD40 immunotherapy. Proc Natl Acad Sci USA. 2020 Jan 7;117(1):541–551. doi: 10.1073/pnas.1902145116
   PubMed Web of Science ®Google Scholar
• Haslam A, Gill J, Prasad V. Estimation of the percentage of us patients with cancer who are eligible for immune checkpoint inhibitor drugs. JAMA Netw Open. 2020 Mar 2;3(3):e200423. doi: 10.1001/jamanetworkopen.2020.0423
   PubMed Web of Science ®Google Scholar